Ann: Form 8-K, page-40

Potential problems that arise from this delay:

1. Enlarged sales force that won’t be able to capitalize on Recell Go for 4-6 more months.

2. Extra unexpected cash burn that could require dilution to continue funding operations before reaching profitability.

3. Slower market penetration of burns and soft tissue indications.

4. Potential delay of Vitiligo rollout.

5. Potential delay of international expansion.

6. Slower than expected growth.

7. Less faith in management resulting in slower investment into the company.

As JC said, Recell Go is what makes everything Go.

When did the company learn about this information? Was it on 8/21/23 when Donna Shiroma, the author of the 8K, sold over 4000 shares of RCEL?